AbbVie Launches New Treatment for Pediatric Crohns in UK

Humiria is a biologic treatment intended for treatment of severe active pediatric cases of the disease.

AbbVie announced today that HUMIRA(R) (adalimumab) is now available for the treatment of paediatric patients aged six to 17 years with severe active Crohn's disease (CD) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications to such therapies. 

No votes yet
Syndicate content